Business Wire

Virgin Media O2 Selects Mavenir for its Open RAN Deployment

17.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Virgin Media O2 has selected Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, as its Open Radio Access Network (Open RAN) vendor. Mavenir will also be the prime integrator, providing its Open virtualised Radio Access Network (Open vRAN) solution for sites on Virgin Media O2’s network.

Virgin Media O2 will work with Mavenir to roll out a scalable Open vRAN solution as part of its network evolution plans and adopt a more flexible and cloud-native architecture.

Mavenir’s Open vRAN solution is built from the ground up to be cloud-native, with fully containerised microservices allowing it to be deployed easily on any cloud. Mavenir’s Open vRAN O-RAN compliant solution works on open interfaces supporting O-RAN Split 7.2x and Split 2.

It further disaggregates into Distributed Unit (DU) and Centralised Unit (CU). These entities work as containerised network functions running on Commercial Off the Shelf (COTS) hardware containing Intel processors.

Designed to support multiple Fronthaul splits simultaneously, the vRAN solution provides a vendor-agnostic and future-proof architecture, leveraging Virgin Media O2’s network infrastructure assets.

Mavenir’s Open RAN system will consist of fully virtualised L1, L2 vRAN SW and will operate on Intel Xeon Scalable Processors, along with Intel vRAN Accelerator ACC100 and Intel 800 series Ethernet adapters. The delivery will also feature Mavenir’s OpenBeam™ Radios including massive MIMO, 3rd party O-RAN based Radio Units (O-RU) for open Fronthaul, network monitoring and optimisation.

Jeanie York, Chief Technology Officer at Virgin Media O2, said: “Through digitalising our networks, we’re seamlessly integrating our infrastructure to get more value from our existing assets. Extending our collaboration with Mavenir to the RAN for the first time will help us establish a future-proof Open vRAN architecture, unlocking the benefits of a multi-vendor open interface while allowing us to rapidly benefit from an end-to-end network solution.”

Pardeep Kohli, President and CEO at Mavenir, said: “Mavenir’s Open vRAN cloud-native approach presents new pathways for automated networks to deliver on the use cases and data demands of today and beyond - driving network elasticity, flexibility and best-in-class automation. The Mavenir OpenBeam radio portfolio fully complements Virgin Media O2’s full spectrum requirements and we look forward to playing an active role in unlocking network automation and openness in the RAN.”

Cristina Rodriguez, Vice President Network and Edge Group at Intel, said: “Open and virtualised RAN represents the future: a flexible and scalable software-defined network. Intel is pleased to collaborate with and be part of the Virgin Media O2 technology journey with Mavenir. Together we are delivering innovation, performance, and we are working towards more sustainable networks.”

Notes to Editors

About Virgin Media O2

Virgin Media O2 launched on 1 June 2021, combining the UK’s largest and most reliable mobile network with a broadband network offering the fastest widely-available broadband speeds. It is a customer-first organisation that brings a range of connectivity services together in one place with a clear mission: to upgrade the nation. Virgin Media O2 is the corporate brand of the 50:50 joint venture between Liberty Global and Telefónica SA, and one of the UK’s largest businesses. The company has 47 million UK connections across broadband, mobile, TV and home phone. Its own fixed network currently passes 16.1 million premises alongside a mobile network that covers 99% of the nation’s population with 4G, and more than 1,600 towns and cities with 5G services targeting 50% population coverage in 2023.

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mavenir PR Contacts:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release

Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye